Shares of Aerie Pharmaceuticals Inc. (AERI) were up over 40% in extended trading on Monday after the company announced that it has received the go-ahead from the FDA to change the primary endpoint range of its second phase III registration trial of Rhopressa, dubbed Rocket 2.